The latest Business updates from the science industry
by Heather Hobbs Oxford Instruments wins King’s Award for Enterprise
Oxford Instruments has been been presented with the King’s Award for Enterprise for Innovation for its Symmetry detector which enables a deeper understanding of material properties through structural analysis at the nanoscale level. An increase in the speed at which in-depth analyses can be performed has resulted in a wider uptake of this approach, said the company.
The detector uses electron backscatter diffraction (EBSD) to analyse surfaces for minuscule weaknesses
or fl aws in the crystalline structure, helping to understand how they came about and how they can be addressed.
With the addition of the detector to an electron microscope chamber, analysis is possible in a matter of minutes – this step-change was made possible by a radically new detector design which combined a fi breoptic lens with a CMOS detector.
This provision of high resolution imagery at high speed has made applications of this technology more widely accessible across a variety of sectors and industries – from developing far more robust and long-lasting batteries and semiconductors, to developing stronger aircraft turbine blades. It has even been used to analyse meteorites to help understand how extra-terrestrial rock formed.
“Symmetry was developed to provide our customers with a step change in performance and has enabled them to achieve signifi cant speed and sensitivity gains as they aim to better understand and improve the properties of materials,” said Dr Ian Wilcock, Managing Director, Oxford Instruments
Making adjustments on the detector
Materials Analysis Group. “It was a tremendous team effort, demonstrating innovation at Oxford Instruments at its best and I am delighted for those efforts to have been recognised with such a prestigious accolade as the King’s Award for Enterprise.”
More information online:
ilmt.co/PL/XOed 62620pr@reply-direct.com
Technology access partnership to advance NDD research
A spin out from IST Austria, Neurolentech’s Platform comprises a vast collection of human-derived neuronal
cell lines from patients with
monogenic and complex neurodevelopmental disorders. Kaerus Bioscience will be using the platform to model the complex neural networks underlying clinical features of genetic NDDs at a cellular level, as well as to investigate the therapeutic potential of its small molecule pipeline for numerous genetic syndromes preclinically.
Fiona Nielsen, CEO of Neurolentech, said: “We are excited to collaborate with Kaerus Bioscience in advancing their programs in the fi eld of neurodevelopmental disorders. Our platform’s unique capabilities offer unparalleled insights into disease mechanisms, facilitating the development of novel therapies.”
Team at Neurolentech
Drug discovery startup Neurolentech, focused on epilepsy and related genetic neurodevelopmental disorders (NDDs), has formed an agreement enabling Kaerus Bioscience to access its NDD Drug Discovery platform and leverage its proprietary cell models and assays for functional screens, to drive advances in this fi eld of research.
Robert Ring, CEO of Kaerus Bioscience, added: “Our partnership with Neurolentech underscores Kaerus’ commitment to leveraging cutting-edge technology and innovative platform approaches to accelerating the discovery of treatments for patients with genetic disorders of neurodevelopment.”
More information online:
ilmt.co/PL/7n01 62621pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148
